GlobeNewswire

Magna Establishes Automatic Share Purchase Plan

Dela

AURORA, Ontario, March 29, 2018 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) today announced that it has established a pre-defined automatic securities purchase plan (the "Plan") with a designated broker to facilitate the purchase for cancellation of Common Shares under its current normal course issuer bid (the "Bid"). The Plan will be implemented effective April 2, 2018. Under the Plan, Magna has provided instructions and strict parameters regarding how its Common Shares may be purchased for cancellation during times when it would ordinarily not be permitted to purchase Common Shares due to regulatory restrictions or self-imposed black-out periods. We impose regular blackouts during the period commencing at 11:59 p.m. of the last day of each fiscal quarter to and including 48 hours after the public announcement of our quarterly or annual financial results. The Plan will terminate on the earliest of the date on which: (a) the purchase limit specified in the Plan has been reached, (b) we terminate the Plan in accordance with its terms, in which case we will issue a press release confirming such termination, and (c) the Bid terminates.

Under the Bid, which commenced on November 15, 2017 and which terminates on November 14, 2018, we are authorized to purchase for cancellation up to 35,800,000 Common Shares. All such purchases of Common Shares under the Bid may be made: (i) on the Toronto Stock Exchange ("TSX") in accordance with the rules and policies of the TSX, (ii) on the New York Stock Exchange in compliance with Rule 10b-18 under the U.S. Securities Exchange Act of 1934, (iii) on other published markets, and/or (iv) pursuant to private agreements or specific share repurchase programs under issuer bid exemption orders issued by the Ontario Securities Commission. All such purchases are included in computing the number of Common Shares purchased under the Bid. As of March 26, 2018, the Corporation has repurchased 4,191,894 Common Shares under the Bid. 

INVESTOR CONTACT
Louis Tonelli, Vice-President, Investor Relations 
louis.tonelli@magna.com  -  905.726.7035

MEDIA CONTACT 
Tracy Fuerst, Director of Corporate Communications & PR
tracy.fuerst@magna.com  -  248.631.5396

OUR BUSINESS (1)

We have more than 168,000 entrepreneurial-minded employees dedicated to delivering mobility solutions. We are a mobility technology company and one of the world's largest automotive suppliers with 335 manufacturing operations and 96 product development, engineering and sales centres in 28 countries. Our competitive capabilities include body exteriors and structures, power and vision technologies, seating systems and complete vehicle solutions. Our common shares trade on the Toronto Stock Exchange (MG) and the New York Stock Exchange (MGA). For further information about Magna, visit www.magna.com.

(1) Manufacturing operations, product development, engineering and sales centres and employee figures include equity-accounted operations.

FORWARD-LOOKING STATEMENTS

This press release may contain statements that, to the extent that they are not recitations of historical fact, constitute "forward-looking statements" within the meaning of applicable securities legislation, including, but not limited to, future purchases of our Common Shares under the Normal Course Issuer Bid, including pursuant to private agreements or a specific share repurchase program under an issuer bid exemption order issued by the Ontario Securities Commission. Forward-looking statements may include financial and other projections, as well as statements regarding our future plans, objectives or economic performance, or the assumptions underlying any of the foregoing. We use words such as "may", "would", "could", "should" "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "outlook", "project", "estimate" and similar expressions suggesting future outcomes or events to identify forward-looking statements. Any such forward-looking statements are based on information currently available to us, and are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. However, whether actual results and developments will conform to our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks, assumptions and uncertainties include, without limitation, the impact of: the potential for a deterioration of economic conditions or an extended period of economic uncertainty; a decline in consumer confidence, which would typically result in lower production volume levels; legal claims and/or regulatory actions against us; fluctuations in relative currency values; changes in laws and governmental regulations; liquidity risks; the unpredictability of, and fluctuation in, the trading price of our Common Shares and other factors set out in our Annual Information Form filed with securities commissions in Canada and our annual report on Form 40-F filed with the United States Securities and Exchange Commission, and subsequent filings. In evaluating forward-looking statements, we caution readers not to place undue reliance on any forward-looking statements and readers should specifically consider the various factors which could cause actual events or results to differ materially from those indicated by such forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Magna International Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum